Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 2/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | HTT | P42858 | 1/20 | 0.50 |
| ▸ | RAB9A | P51151 | 1/20 | 0.50 |
| ▸ | HCAR2 | Q8TDS4 | 2/20 | 0.43 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.41 |
| ▸ | PIK3CA | P42336 | 2/20 | 0.40 |
| ▸ | CA1 | P00915 | 3/20 | 0.39 |
| ▸ | CA2 | P00918 | 3/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.39 |
| ▸ | CA12 | O43570 | 2/20 | 0.39 |
| ▸ | CA4 | P22748 | 2/20 | 0.39 |
| ▸ | CA6 | P23280 | 2/20 | 0.39 |
| ▸ | CA7 | P43166 | 2/20 | 0.39 |
| ▸ | CA9 | Q16790 | 2/20 | 0.39 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.39 |
| ▸ | CA3 | P07451 | 1/20 | 0.39 |
| ▸ | PKM | P14618 | 1/20 | 0.39 |
| ▸ | CA5A | P35218 | 1/20 | 0.39 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7652014 | 0.87 | PTGS2 (0.55) | MAPK1LMNAHTTRAB9APTGS2 | |
| SCHEMBL29612133 | 0.87 | PTGS2 (0.55) | MAPK1LMNAHTTRAB9APTGS2 | |
| SCHEMBL31599495 | 0.86 | PIK3CA (0.40) | MAPK1LMNAHTTRAB9APIK3CA | |
| SCHEMBL17173718 | 0.86 | PIK3CA (0.40) | MAPK1LMNAHTTRAB9APIK3CA | |
| SCHEMBL30151852 | 0.84 | NNMT (0.49) | PIK3CACA1CA2 | |
| SCHEMBL29918163 | 0.84 | MAPK1 (0.46) | MAPK1LMNARAB9APIK3CACA1 | |
| SCHEMBL1063745 | 0.84 | MAPK1 (0.46) | MAPK1LMNARAB9APIK3CACA1 | |
| SCHEMBL3369108 | 0.83 | MAPT (0.50) | MAPK1LMNAHTTRAB9AHCAR2 | |
| SCHEMBL14908756 | 0.82 | HCAR3 (0.43) | MAPK1LMNAHTTRAB9AHCAR2 | |
| SCHEMBL23166438 | 0.81 | HDAC1 (0.51) | PIK3CA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 72 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3856179-B1 | MONOACYLGLYCEROL LIPASE MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2026-05-13 | — | — | EP | disclosed |
| EP-4673447-A1 | [1,3]THIAZOLO[4,5-D]-PYRIMIDIN-7-ONES AS INHIBITORS OF NOX4 | Boehringer Ingelheim International GmbH (DE) | 2026-01-07 | — | — | EP | disclosed |
| US-20250214970-A1 | PYRIDINYLACETAMIDE DERIVATIVES AS SODIUM CHANNEL ACTIVATORS | XENON PHARMACEUTICALS INC. (CA) | 2025-07-03 | — | — | US | disclosed |
| US-20250129044-A1 | PYRIDINYL DERIVATIVES AS SODIUM CHANNEL ACTIVATORS | XENON PHARMACEUTICALS INC. (CA) | 2025-04-24 | — | — | US | disclosed |
| CN-114163437-B | Substituted pyrazolo [1,5-a ] pyridine compounds as RET kinase inhibitors | 阿雷生物药品公司 | 2025-03-04 | — | — | CN | disclosed |
| US-20240327429-A1 | [1,3]Thiazolo[4,5-d]-pyrimidon-7-ones as inhibitors of NOX4 | BOEHRINGER INGELHEIM INT (DE) | 2024-10-03 | — | — | US | disclosed |
| US-20240327410-A1 | Monoacylglycerol Lipase Modulators | JANSSEN PHARMACEUTICA NV (BE) | 2024-10-03 | — | — | US | disclosed |
| CN-113164458-B | Monoacylglycerol lipase modulators | 詹森药业有限公司 | 2024-09-13 | — | — | CN | disclosed |
| WO-2024180018-A1 | [1,3]THIAZOLO[4,5-D]-PYRIMIDIN-7-ONES AS INHIBITORS OF NOX4 | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2024-09-06 | — | — | WO | disclosed |
| EP-4405344-A2 | PYRIDINYL DERIVATIVES AS SODIUM CHANNEL ACTIVATORS | Xenon Pharmaceuticals Inc. (CA) | 2024-07-31 | — | — | EP | disclosed |
| US-20130116430-A1 | NOVEL NICOTINAMIDE DERIVATIVE OR SALT THEREOF | FUJIFILM CORPORATION (JP) | 2013-05-09 | — | — | US | disclosed |
| EP-2589592-A1 | NOVEL NICOTINAMIDE DERIVATIVES OR SALTS THEREOF | FUJIFILM Corporation (JP) | 2013-05-08 | — | — | EP | disclosed |
| EP-2589592-A1 | NOVEL NICOTINAMIDE DERIVATIVES OR SALTS THEREOF | FUJIFILM Corporation (JP) | 2013-05-08 | — | — | EP | disclosed |
| US-8263627-B2 | Pyridyl amide T-type calcium channel antagonists | MERCK SHARP & DOHME CORP. (US) | 2012-09-11 | — | — | US | disclosed |
| WO-2012002577-A1 | NOVEL NICOTINAMIDE DERIVATIVES OR SALTS THEREOF | 富士フイルム株式会社 (JP) | 2012-01-05 | — | — | WO | disclosed |
| US-20110112064-A1 | Pyridyl Amide T-Type Calcium Channel Antagonists | MERCK SHARP & DOHME CORP. (US) | 2011-05-12 | — | — | US | disclosed |
| US-7875636-B2 | 2-(4-isopropenylphenyl)-N-[(1R)-1-(5-(2,2,2-trifluoroethoxy)pyridin-2-yl)ethyl]acetamide; epilepsy, pain, neuropathic pain, schizophrenia, Parkinson's disease, depression, anxiety, sleep disorders, psychosis, schizophrenia, cardiac arrhythmia and hypertension | MERCK SHARP & DOHME CORP. (US) | 2011-01-25 | — | — | US | disclosed |
| US-20090275550-A1 | Pyridyl Amide T-Type Calcium Channel Antagonists | MERCK SHARP & DOHME LLC | 2009-11-05 | — | — | US | disclosed |
| EP-2010493-A2 | PYRIDYL AMIDE T-TYPE CALCIUM CHANNEL ANTAGONISTS | Merck & Co., Inc. (US) | 2009-01-07 | — | — | EP | disclosed |
| WO-2007120729-A2 | PYRIDYL AMIDE T-TYPE CALCIUM CHANNEL ANTAGONISTS | MERCK & CO., INC. (US) | 2007-10-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110112064-A1 | Pyridyl Amide T-Type Calcium Channel Antagonists | CACNA1G, CACNA1H, CACNA1I | MAPK1 3357/4885LMNA 1410/4885HTT 765/4885 |
| US-20130116430-A1 | NOVEL NICOTINAMIDE DERIVATIVE OR SALT THEREOF | SYK, CD38, BTK | MAPK1 334/4885LMNA 3649/4885HTT 2347/4885 |
| US-20240327429-A1 | [1,3]Thiazolo[4,5-d]-pyrimidon-7-ones as inhibitors of NOX4 | NOX4, NOX1, NOX5 | MAPK1 1225/4885LMNA 4251/4885HTT 2904/4885 |
| US-20250129044-A1 | PYRIDINYL DERIVATIVES AS SODIUM CHANNEL ACTIVATORS | SCN1B, SCN1A, SCN2B | MAPK1 1372/4885LMNA 287/4885HTT 4258/4885 |
| US-20090275550-A1 | Pyridyl Amide T-Type Calcium Channel Antagonists | CACNA1G, CACNA1H, CACNA1I | MAPK1 3357/4885LMNA 1410/4885HTT 765/4885 |
| US-20250214970-A1 | PYRIDINYLACETAMIDE DERIVATIVES AS SODIUM CHANNEL ACTIVATORS | SCN1A, SCN3A, SCN2A | MAPK1 1466/4885LMNA 442/4885HTT 3750/4885 |
| US-20240327410-A1 | Monoacylglycerol Lipase Modulators | MGLL, LPL, PNLIP | MAPK1 4069/4885LMNA 1845/4885HTT 3309/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.